ARTICLE

GLOBAL PREVALENCE AND MORTALITY OF TYPE2 DIABETES FROM 1990 TO 2019 WITH FUTURE PROJECTIONS TO 2023 AND 2050 A SYSTEMATIC REVIEW

  1. HOME
  2. ARTICLE

01 Pages : 1-10

http://dx.doi.org/10.31703/gdddr.2024(IX-I).01      10.31703/gdddr.2024(IX-I).01      Published : Mar 2024

Global Prevalence and Mortality of Type-2 Diabetes from 1990 to 2019, with Future Projections to 2023 and 2050: a Systematic Review

Abstract

    Type-2 diabetes (T2DM) is a key public health issue due to its high prevalence and mortality rate. This review estimates future global trends in T2DM prevalence and mortality using the Forecast exponential smoothing (ETS) model. By 2050, estimated prevalence and mortality for all ages are 10.23% and 2.05 million, respectively, and for adults (>20 years) are 11.97% and 1.9 million. Obesity and high BMI are key risk factors. Mortality is higher in adults due to polypharmacy and complications. T2DM prevalence and mortality will continue to rise alarmingly. Urgent international and national measures are needed to address this burden. Collaboration between researchers, clinicians, and policymakers is crucial for optimal health planning and mitigating the impact of T2DM.

    Type-2 Diabetes, Prevalence, Mortality, Forecast

    (1) Hafiz Muhammad Usman Abid
    Assistant Professor, Tahseen Ahmad Cheema Institute, Bahawalpur, Punjab, Pakistan.
    (2) Muhammad Hanif
    Associate Professor, Department of Pharmaceutics, Faculty of Pharmacy, Bahauddin Zakariya University, Multan, Punjab, Pakistan.
    (3) Muhammad Naveed Bin Afzal
    Department of Pharmaceutics, Faculty of Pharmacy, The Islamia University of Bahawalpur, Punjab, Pakistan.
    (4) Muhammad Azeem
    Hamdard Institute of Pharmaceutical Sciences, Hamdard University Islamabad, Pakistan.
    (5) Dur e Shahwar
    Department of Pharmaceutics, Faculty of Pharmacy, Bahauddin Zakariya University, Multan, Punjab, Pakistan.
    (6) Khalid Mahmood
    Associate Professor, Institute of Chemical Sciences, Bahauddin Zakariya University Multan, Punjab, Pakistan.
Fulltext PDF

References

  • Institute for Health Metrics and Evaluation (IHME). (2019). Global Burden of Disease (GBD) 2019. https://vizhub.healthdata.org/gbd-results/ 

  • Institute for Health Metrics and Evaluation (IHME). (2019). Global Burden of Disease (GBD) 2019. https://vizhub.healthdata.org/gbd-results/ 

  • The International Diabetes Federation (IDF). (2024). Type 2 diabetes. https://idf.org/about-diabetes/type-2-diabetes/
  • The International Diabetes Federation (IDF). (2024). Type 2 diabetes. https://idf.org/about-diabetes/type-2-diabetes/
  • Khan, M. a. B., Hashim, M. J., King, J. K., Govender, R. D., Mustafa, H., & Kaabi, J. A. (2019). Epidemiology of Type 2 Diabetes – Global burden of disease and Forecasted Trends. Journal of Epidemiology and Global Health, 10(1), 107. https://doi.org/10.2991/jegh.k.191028.001
  • Khan, M. a. B., Hashim, M. J., King, J. K., Govender, R. D., Mustafa, H., & Kaabi, J. A. (2019). Epidemiology of Type 2 Diabetes – Global burden of disease and Forecasted Trends. Journal of Epidemiology and Global Health, 10(1), 107. https://doi.org/10.2991/jegh.k.191028.001
  •  Bellary, S., Kyrou, I., Brown, J. E., & Bailey, C. J. (2021). Type 2 diabetes mellitus in older adults: clinical considerations and management. Nature Reviews Endocrinology, 17(9), 534–548. https://doi.org/10.1038/s41574-021-00512-2
  •  Bommer, C., Heesemann, E., Sagalova, V., Manne-Goehler, J., Atun, R., Bärnighausen, T., & Vollmer, S. (2017). The global economic burden of diabetes in adults aged 20–79 years: a cost-of-illness study. The Lancet Diabetes & Endocrinology, 5(6), 423–430. https://doi.org/10.1016/s2213-8587(17)30097-9
  •  Bommer, C., Heesemann, E., Sagalova, V., Manne-Goehler, J., Atun, R., Bärnighausen, T., & Vollmer, S. (2017). The global economic burden of diabetes in adults aged 20–79 years: a cost-of-illness study. The Lancet Diabetes & Endocrinology, 5(6), 423–430. https://doi.org/10.1016/s2213-8587(17)30097-9
  • Chatterjee, S., Khunti, K., & Davies, M. J. (2017). Type 2 diabetes. The Lancet, 389(10085), 2239–2251. https://doi.org/10.1016/s0140-6736(17)30058-2
  • Cho, N., Shaw, J., Karuranga, S., Huang, Y., Da Rocha Fernandes, J., Ohlrogge, A., & Malanda, B. (2018). IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Research and Clinical Practice, 138, 271–281. https://doi.org/10.1016/j.diabres.2018.02.023
  • Diaz-Valencia, P. A., Bougnères, P., & Valleron, A. (2015). Global epidemiology of type 1 diabetes in young adults and adults: a systematic review. BMC Public Health, 15(1). https://doi.org/10.1186/s12889-015-1591-y
  • Diaz-Valencia, P. A., Bougnères, P., & Valleron, A. (2015). Global epidemiology of type 1 diabetes in young adults and adults: a systematic review. BMC Public Health, 15(1). https://doi.org/10.1186/s12889-015-1591-y
  •  Galicia-Garcia, U., Benito-Vicente, A., Jebari, S., Larrea-Sebal, A., Siddiqi, H., Uribe, K. B., Ostolaza, H., & Martín, C. (2020). Pathophysiology of Type 2 diabetes mellitus. International Journal of Molecular Sciences, 21(17), 6275. https://doi.org/10.3390/ijms21176275
  •  Guzman-Vilca, W. C., & Carrillo-Larco, R. M. (2024). Number of People with Type 2 Diabetes Mellitus in 2035 and 2050: A Modelling Study in 188 Countries. Current Diabetes Reviews, 20. https://doi.org/10.2174/0115733998274323231230131843
  •  Guzman-Vilca, W. C., & Carrillo-Larco, R. M. (2024). Number of People with Type 2 Diabetes Mellitus in 2035 and 2050: A Modelling Study in 188 Countries. Current Diabetes Reviews, 20. https://doi.org/10.2174/0115733998274323231230131843
  • Jalilian, H., Heydari, S., Imani, A., Salimi, M., Mir, N., & Najafipour, F. (2023). Economic burden of type 2 diabetes in Iran: A cost‐of‐illness study. Health Science Reports, 6(2). https://doi.org/10.1002/hsr2.1120
  • Magliano, D. J., & Boyko, E. J. (2022). IDF diabetes atlas. 
  • Marmot, M. (2005). Social determinants of health inequalities. The Lancet, 365(9464), 1099–1104. https://doi.org/10.1016/s0140-6736(05)71146-6
  •  Müller, J. A., Groß, R., Conzelmann, C., Krüger, J., Merle, U., Steinhart, J., Weil, T., Koepke, L., Bozzo, C. P., Read, C., Fois, G., Eiseler, T., Gehrmann, J., Van Vuuren, J., Wessbecher, I. M., Frick, M., Costa, I. G., Breunig, M., Grüner, B., . . . Kleger, A. (2021). SARS-CoV-2 infects and replicates in cells of the human endocrine and exocrine pancreas. Nature Metabolism, 3(2), 149–165. https://doi.org/10.1038/s42255-021-00347-1
  •  Müller, J. A., Groß, R., Conzelmann, C., Krüger, J., Merle, U., Steinhart, J., Weil, T., Koepke, L., Bozzo, C. P., Read, C., Fois, G., Eiseler, T., Gehrmann, J., Van Vuuren, J., Wessbecher, I. M., Frick, M., Costa, I. G., Breunig, M., Grüner, B., . . . Kleger, A. (2021). SARS-CoV-2 infects and replicates in cells of the human endocrine and exocrine pancreas. Nature Metabolism, 3(2), 149–165. https://doi.org/10.1038/s42255-021-00347-1
  • United Nations. (2022). World population prospects 2022. https://www.un.org/development/desa/pd/sites/www.un.org.development.desa.pd/files/wpp2022_summary_of_results.pdf
  • United Nations. (2015). On World Diabetes Day, UN calls for greater action to turn tide of growing global epidemic. United Nations. https://news.un.org/en/story/2015/11/515422#:~:text=WHO%20projects%20that%20diabetes%20will,require%20insulin%20injections%20for%20survival
  • Ong, K. L., Stafford, L. K., McLaughlin, S. A., Boyko, E. J., Vollset, S. E., Smith, A. E., . . . Hagins, H. (2023). Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. The Lancet. 
  • Ong, K. L., Stafford, L. K., McLaughlin, S. A., Boyko, E. J., Vollset, S. E., Smith, A. E., . . . Hagins, H. (2023). Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. The Lancet. 
  • Rathmann, W., Kuss, O., & Kostev, K. (2022). Incidence of newly diagnosed diabetes after Covid-19. Diabetologia, 65(6), 949–954. https://doi.org/10.1007/s00125-022-05670-0
  • Remelli, F., Ceresini, M. G., Trevisan, C., Noale, M., & Volpato, S. (2022). Prevalence and impact of polypharmacy in older patients with type 2 diabetes. Aging Clinical and Experimental Research, 34(9), 1969–1983. https://doi.org/10.1007/s40520-022-02165-1
  • Safiri, S., Karamzad, N., Kaufman, J. S., Bell, A. W., Nejadghaderi, S. A., Sullman, M. J. M., Moradi-Lakeh, M., Collins, G., & Kolahi, A. (2022). Prevalence, Deaths and Disability-Adjusted-Life-Years (DALYs) due to Type 2 Diabetes and its attributable risk factors in 204 countries and territories, 1990-2019: Results from the Global Burden of Disease Study 2019. Frontiers in Endocrinology, 13. https://doi.org/10.3389/fendo.2022.838027
  • Safiri, S., Karamzad, N., Kaufman, J. S., Bell, A. W., Nejadghaderi, S. A., Sullman, M. J. M., Moradi-Lakeh, M., Collins, G., & Kolahi, A. (2022). Prevalence, Deaths and Disability-Adjusted-Life-Years (DALYs) due to Type 2 Diabetes and its attributable risk factors in 204 countries and territories, 1990-2019: Results from the Global Burden of Disease Study 2019. Frontiers in Endocrinology, 13. https://doi.org/10.3389/fendo.2022.838027
  • Starling, S. (2021). How COVID-19 disrupts glycometabolic control. Nature Reviews Endocrinology, 17(8), 448-448. 
  • Sun, H., Saeedi, P., Karuranga, S., Pinkepank, M., Ogurtsova, K., Duncan, B. B., Stein, C., Basit, A., Chan, J. C., Mbanya, J. C., Pavkov, M. E., Ramachandaran, A., Wild, S. H., James, S., Herman, W. H., Zhang, P., Bommer, C., Kuo, S., Boyko, E. J., & Magliano, D. J. (2022). IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Research and Clinical Practice, 183, 109119. https://doi.org
  • Sun, H., Saeedi, P., Karuranga, S., Pinkepank, M., Ogurtsova, K., Duncan, B. B., Stein, C., Basit, A., Chan, J. C., Mbanya, J. C., Pavkov, M. E., Ramachandaran, A., Wild, S. H., James, S., Herman, W. H., Zhang, P., Bommer, C., Kuo, S., Boyko, E. J., & Magliano, D. J. (2022). IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Research and Clinical Practice, 183, 109119. https://doi.org
  • Tancredi, M., Rosengren, A., Svensson, A., Kosiborod, M., Pivodic, A., Gudbjörnsdottir, S., Wedel, H., Clements, M., Dahlqvist, S., & Lind, M. (2015). Excess Mortality among Persons with Type 2 Diabetes. New England Journal of Medicine, 373(18), 1720–1732. https://doi.org/10.1056/nejmoa1504347
  •  Topór-Mądry, R. (2017). Health Effects of Overweight and Obesity in 195 Countries over 25 Years. New England Journal of Medicine, 377(1). 
  •  Topór-Mądry, R. (2017). Health Effects of Overweight and Obesity in 195 Countries over 25 Years. New England Journal of Medicine, 377(1). 
  • UK, T. B. D. A. o. a. D. (2024). Complications of diabetes. The British Diabetic Association operating as Diabetes UK. https://www.diabetes.org.uk/guide-to-diabetes/complications
  • Whitmore, C. (2010). Type 2 diabetes and obesity in adults. British Journal of Nursing, 19(14), 880–886. https://doi.org/10.12968/bjon.2010.19.14.49041
  • Ye, J., Wu, Y., Yang, S., Zhu, D., Chen, F., Chen, J., Ji, X., & Hou, K. (2023). The global, regional and national burden of type 2 diabetes mellitus in the past, present and future: a systematic analysis of the Global Burden of Disease Study 2019. Frontiers in Endocrinology, 14. https://doi.org/10.3389/fendo.2023.1192629
  • Ye, J., Wu, Y., Yang, S., Zhu, D., Chen, F., Chen, J., Ji, X., & Hou, K. (2023). The global, regional and national burden of type 2 diabetes mellitus in the past, present and future: a systematic analysis of the Global Burden of Disease Study 2019. Frontiers in Endocrinology, 14. https://doi.org/10.3389/fendo.2023.1192629

Cite this article

APA

    APA : Abid, H. M. U., Hanif, M., & Afzal, M. N. B. (2024). Global Prevalence and Mortality of Type-2 Diabetes from 1990 to 2019, with Future Projections to 2023 and 2050: a Systematic Review. Global Drug Design & Development Review, IX(I), 1-10. https://doi.org/10.31703/gdddr.2024(IX-I).01

CHICAGO

    CHICAGO : Abid, Hafiz Muhammad Usman, Muhammad Hanif, and Muhammad Naveed Bin Afzal. 2024. "Global Prevalence and Mortality of Type-2 Diabetes from 1990 to 2019, with Future Projections to 2023 and 2050: a Systematic Review." Global Drug Design & Development Review, IX (I): 1-10 doi: 10.31703/gdddr.2024(IX-I).01

HARVARD

    HARVARD : ABID, H. M. U., HANIF, M. & AFZAL, M. N. B. 2024. Global Prevalence and Mortality of Type-2 Diabetes from 1990 to 2019, with Future Projections to 2023 and 2050: a Systematic Review. Global Drug Design & Development Review, IX, 1-10.

MHRA

    MHRA : Abid, Hafiz Muhammad Usman, Muhammad Hanif, and Muhammad Naveed Bin Afzal. 2024. "Global Prevalence and Mortality of Type-2 Diabetes from 1990 to 2019, with Future Projections to 2023 and 2050: a Systematic Review." Global Drug Design & Development Review, IX: 1-10

MLA

    MLA : Abid, Hafiz Muhammad Usman, Muhammad Hanif, and Muhammad Naveed Bin Afzal. "Global Prevalence and Mortality of Type-2 Diabetes from 1990 to 2019, with Future Projections to 2023 and 2050: a Systematic Review." Global Drug Design & Development Review, IX.I (2024): 1-10 Print.

OXFORD

    OXFORD : Abid, Hafiz Muhammad Usman, Hanif, Muhammad, and Afzal, Muhammad Naveed Bin (2024), "Global Prevalence and Mortality of Type-2 Diabetes from 1990 to 2019, with Future Projections to 2023 and 2050: a Systematic Review", Global Drug Design & Development Review, IX (I), 1-10

TURABIAN

    TURABIAN : Abid, Hafiz Muhammad Usman, Muhammad Hanif, and Muhammad Naveed Bin Afzal. "Global Prevalence and Mortality of Type-2 Diabetes from 1990 to 2019, with Future Projections to 2023 and 2050: a Systematic Review." Global Drug Design & Development Review IX, no. I (2024): 1-10. https://doi.org/10.31703/gdddr.2024(IX-I).01